KBC Group
RLAY icon

KBC Group’s Relay Therapeutics RLAY Stock Holding History

KBC Group’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$62K Hold
3,448
– – ﹤0.01% 1652
2026
Q2 		$65K Hold
3,448
– – ﹤0.01% 1625
2026
Q1 		$34K Buy
+3,448
New +$30.8K ﹤0.01% 1771

Other funds holding RLAY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Jupiter Asset Management
Jupiter Asset Management London, United Kingdom $21.4B AUM 19.74% 1-Year Est. Return

KBC Group's RLAY Position: Q3 2026 in Review

KBC Group held its Relay Therapeutics (RLAY) position steady in Q3 2026 at 3,448 shares worth $62K. The position accounts for ﹤0.01% of the portfolio, ranked #1652.

KBC Group first reported a position in RLAY in Q1 2026 and has held it in 3 quarters since. The position peaked at $65K in Q2 2026. 109 funds tracked by Wall St. Rank hold RLAY as of Q3 2026.

  • KBC Group held 3,448 shares of Relay Therapeutics worth $62K as of Q3 2026.
  • KBC Group left its Relay Therapeutics share count unchanged in Q3 2026.
  • Relay Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1652 holding.
  • KBC Group first reported a position in Relay Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • KBC Group's Relay Therapeutics position peaked at $65K in Q2 2026.
  • 109 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.